|

Reduced dose intensity of IO Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • UNICANCER1

Indications

  • Liver Disease1
  • Squamous Skin Carcinoma1
  • Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma1
  • Colorectal Carcinoma With Microsatellite Instability1
  • Endometrial Carcinoma1

Other1 trial

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.